Interleukin-mediated therapies in liver diseases and comorbidity effects

[en] Cytokines like interleukins (ILs) play important roles in inflammation and innate immune. Yang and Zhang carried out an interesting study related to ILs and hepatic diseases. They described the role of ILs in the pathogenesis and resolution of hepatic disorders. The authors summarized alcohol-related liver disease and virus-induced hepatitis, as far as clinical studies a fortiori carried out on IL-mediated treatments pertaining to these dysfunctions. This editorial contributes to the review by Yang and Zhang titled, "Interleukins in liver disease treatment", and focuses on therapies mediated by ILs in comorbid liver diseases. The documentary search was conducted on recent pertinent literature, primarily using the Google Scholar and PubMed databases.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Bouare, Nouhoum

Delwaide, Jean ; Université de Liège - ULiège > Département des sciences cliniques ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive

Language :

English

Title :

Interleukin-mediated therapies in liver diseases and comorbidity effects

Publication date :

27 July 2024

Journal title :

World Journal of Hepatology

eISSN :

1948-5182

Publisher :

Baishideng Publishing Group Inc.

Volume :

Issue :

Pages :

980-989

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.wjgnet.com/1948-5182/full/v16/i7/980.htm

Available on ORBi :

since 27 July 2024

Statistics

Number of views

32 (3 by ULiège)

Number of downloads

18 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

1 Liles WC, Van Voorhis WC. Review: nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. J Infect Dis 1995; 172: 1573-1580 [PMID: 7594719 DOI: 10.1093/infdis/172.6.1573]
2 Justiz Vaillant AA, Qurie A. Interleukin. 2022 Aug 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan- [PMID: 29763015]
3 Van Damme J, Opdenakker G, Van Damme S, Struyf S. Antibodies as tools in cytokine discovery and usage for diagnosis and therapy of inflammatory diseases. Eur Cytokine Netw 2023; 34: 1-9 [PMID: 37387364 DOI: 10.1684/ecn.2023.0484]
4 Yang M, Zhang CY. Interleukins in liver disease treatment. World J Hepatol 2024; 16: 140-145 [PMID: 38495285 DOI: 10.4254/wjh.v16.i2.140]
5 Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, Lee K, Stave CD, Henry L, Barnett SD, Cheung R, Nguyen MH. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol 2023; 79: 287-295 [PMID: 37040843 DOI: 10.1016/j.jhep.2023.03.040]
6 Nysather J, Kaya E, Manka P, Gudsoorkar P, Syn WK. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk. Adv Kidney Dis Health 2023; 30: 315-335 [PMID: 37657879 DOI: 10.1053/j.akdh.2023.04.001]
7 Agustanti N, Soetedjo NNM, Damara FA, Iryaningrum MR, Permana H, Bestari MB, Supriyadi R. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis. Diabetes Metab Syndr 2023; 17: 102780 [PMID: 37201293 DOI: 10.1016/j.dsx.2023.102780]
8 Pal SC, Méndez-Sánchez N. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. World J Gastroenterol 2023; 29: 3999-4008 [PMID: 37476582 DOI: 10.3748/wjg.v29.i25.3999]
9 Khairnar R, Islam MA, Fleishman J, Kumar S. Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics. Life Sci 2023; 312: 121185 [PMID: 36375569 DOI: 10.1016/j.lfs.2022.121185]
10 Samuel S, Abulawi A, Malik R. Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation. Gastroenterol Insights 2023; 14: 249-270 [DOI: 10.3390/gastroent14030018]
11 Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2023; 20: 708-722 [PMID: 37402873 DOI: 10.1038/s41575-023-00800-4]
12 A Rahman NA, Balasubramaniam VRMT, Yap WB. Potential of Interleukin (IL)-12 Group as Antivirals: Severe Viral Disease Prevention and Management. Int J Mol Sci 2023; 24 [PMID: 37108513 DOI: 10.3390/ijms24087350]
13 Araújo A, Sgorlon G, Aguiar LE, Cidrão MHMC, Teixeira KS, Villalobos Salcedo JM, Passos-Silva AM, Vieira D. Influence of polymorphic variations of IFNL, HLA, and IL-6 genes in severe cases of COVID-19. Exp Biol Med (Maywood) 2023; 248: 787-797 [PMID: 37452704 DOI: 10.1177/15353702231181343]
14 Deb S, Arrighi S. Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients. Eur J Drug Metab Pharmacokinet 2021; 46: 185-203 [PMID: 33538960 DOI: 10.1007/s13318-020-00668-8]
15 El-Kassas M, Alboraie M, Elbadry M, El Sheemy R, Abdellah M, Afify S, Madkour A, Zaghloul M, Awad A, Wifi MN, Al Balakosy A, Eltabbakh M. Non-pulmonary involvement in COVID-19: A systemic disease rather than a pure respiratory infection. World J Clin Cases 2023; 11: 493-505 [PMID: 36793640 DOI: 10.12998/wjcc.v11.i3.493]
16 Walia D, Saraya A, Gunjan D. COVID-19 in patients with pre-existing chronic liver disease - predictors of outcomes. World J Virol 2023; 12: 30-43 [PMID: 36743659 DOI: 10.5501/wjv.v12.i1.30]
17 Guarino M, Cossiga V, Cutolo FM, Attanasio MR, Lieto R, Morisco F. COVID-19 and Fatty Liver Disorders. J Clin Med 2023; 12 [PMID: 37445349 DOI: 10.3390/jcm12134316]
18 Chakraborty R, Sharma D, Kapoor DU, Dwivedi A, Khabiya R, Sen S. Implications of metabolic dysfunction associated fatty liver disease in COVID-19. World J Clin Cases 2023; 11: 1275-1286 [PMID: 36926128 DOI: 10.12998/wjcc.v11.i6.1275]
19 Silaghi-Dumitrescu R, Patrascu I, Lehene M, Bercea I. Comorbidities of COVID-19 Patients. Medicina (Kaunas) 2023; 59 [PMID: 37629683 DOI: 10.3390/medicina59081393]
20 Giuli L, Maestri M, Santopaolo F, Pompili M, Ponziani FR. Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease. Metabolites 2023; 13 [PMID: 37367929 DOI: 10.3390/metabo13060772]
21 Drapkina OM, Elkina AY, Sheptulina AF, Kiselev AR. Non-Alcoholic Fatty Liver Disease and Bone Tissue Metabolism: Current Findings and Future Perspectives. Int J Mol Sci 2023; 24 [PMID: 37176153 DOI: 10.3390/ijms24098445]
22 Rosenblum SL. Inflammation, dysregulated iron metabolism, and cardiovascular disease. Front Aging 2023; 4: 1124178 [PMID: 36816471 DOI: 10.3389/fragi.2023.1124178]
23 Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol 2018; 179: 16-29 [PMID: 29235656 DOI: 10.1111/bjd.16239]
24 Díaz LA, Arab JP, Louvet A, Bataller R, Arrese M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2023; 20: 764-783 [PMID: 37582985 DOI: 10.1038/s41575-023-00822-y]
25 Kim GA, Moon JH, Kim W. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity. Clin Mol Hepatol 2023; 29: 831-843 [PMID: 37634892 DOI: 10.3350/cmh.2023.0277]
26 Wang H, Wu J, Ma L, Bai Y, Liu J. The role of interleukin -1 family in fibrotic diseases. Cytokine 2023; 165: 156161 [PMID: 36921509 DOI: 10.1016/j.cyto.2023.156161]
27 Jensen AH, Ytting H, Winther-Sørensen M, Burisch J, Bergquist A, Gluud LL, Wewer Albrechtsen NJ. Autoimmune liver diseases and diabetes. Eur J Gastroenterol Hepatol 2023; 35: 938-947 [PMID: 37505973 DOI: 10.1097/MEG.0000000000002594]
28 Kotlyarov S. Immune and metabolic cross-links in the pathogenesis of comorbid non-alcoholic fatty liver disease. World J Gastroenterol 2023; 29: 597-615 [PMID: 36742172 DOI: 10.3748/wjg.v29.i4.597]
29 Mohib M, Afnan K, Paran TZ, Khan S, Sarker J, Hasan N, Hasan I, Sagor AT. Beneficial Role of Citrus Fruit Polyphenols Against Hepatic Dysfunctions: A Review. J Diet Suppl 2018; 15: 223-250 [PMID: 28641051 DOI: 10.1080/19390211.2017.1330301]
30 Balak DMW, Piaserico S, Kasujee I. Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. Psoriasis (Auckl) 2021; 11: 151-168 [PMID: 34909410 DOI: 10.2147/PTT.S342911]
31 Maestri M, Santopaolo F, Pompili M, Gasbarrini A, Ponziani FR. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies. Front Nutr 2023; 10: 1110536 [PMID: 36875849 DOI: 10.3389/fnut.2023.1110536]
32 Wang Y, Wang Z, Wan Y, Jin F, Shi X, Xing Z, Tian B, Li B. Assessing the in vivo ameliorative effects of Lactobacillus acidophilus KLDS1.0901 for induced non-alcoholic fatty liver disease treatment. Front Nutr 2023; 10: 1147423 [PMID: 37020807 DOI: 10.3389/fnut.2023.1147423]
33 Jafarirad S, Goodarzi R, Mohammadtaghvaei N, Dastoorpoor M, Alavinejad P. Effectiveness of the pomegranate extract in improving hepatokines and serum biomarkers of non-alcoholic fatty liver disease: A randomized double blind clinical trial. Diabetes Metab Syndr 2023; 17: 102693 [PMID: 36535123 DOI: 10.1016/j.dsx.2022.102693]
34 Sanz-cánovas J, Ricci M, Cobos-palacios L, López-sampalo A, Hernández-negrín H, Vázquez-márquez M, Mancebo-sevilla JJ, Álvarez-recio E, López-carmona MD, Pérez-velasco MÁ, Pérez-belmonte LM, Gómez-huelgas R, Bernal-lópez M. Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases. Rev Cardiovasc Med 2023; 24: 36
35 Yang Y, Jia X, Qu M, Yang X, Fang Y, Ying X, Zhang M, Wei J, Pan Y. Exploring the potential of treating chronic liver disease targeting the PI3K/Akt pathway and polarization mechanism of macrophages. Heliyon 2023; 9: e17116 [PMID: 37484431 DOI: 10.1016/j.heliyon.2023.e17116]
36 Pais R, Cariou B, Noureddin M, Francque S, Schattenberg JM, Abdelmalek MF, Lalazar G, Varma S, Dietrich J, Miller V, Sanyal A, Ratziu V; Liver Forum NAFLD-Associated Comorbidities Working Group. A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials. J Hepatol 2023; 79: 829-841 [PMID: 37001695 DOI: 10.1016/j.jhep.2023.03.014]
37 Pirola CJ, Sookoian S. Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making. Expert Rev Gastroenterol Hepatol 2023; 17: 317-324 [PMID: 36912694 DOI: 10.1080/17474124.2023.2191190]
38 Yoon EL, Kim W. Current and future treatment for alcoholic-related liver diseases. J Gastroenterol Hepatol 2023; 38: 1218-1226 [PMID: 37300449 DOI: 10.1111/jgh.16257]
39 Hwang S, Hicks A, Hoo CZ, Kwon YS, Cho YE, Moore J, Gao B. Novel treatment of acute and acute-on-chronic liver failure: Interleukin-22. Liver Int 2023 [PMID: 37208937 DOI: 10.1111/liv.15619]
40 Fuochi E, Anastasio L, Lynch EN, Campani C, Dragoni G, Milani S, Galli A, Innocenti T. Main factors influencing long-term outcomes of liver transplantation in 2022. World J Hepatol 2023; 15: 321-352 [PMID: 37034235 DOI: 10.4254/wjh.v15.i3.321]
41 Nimphy J, Ibrahim S, Dayoub R, Kubitza M, Melter M, Weiss TS. Interleukin-1ß Attenuates Expression of Augmenter of Liver Regeneration (ALR) by Regulating HNF4α Independent of c-Jun. Int J Mol Sci 2023; 24 [PMID: 37175814 DOI: 10.3390/ijms24098107]
42 Rafaqat S, Gluscevic S, Mercantepe F, Rafaqat S, Klisic A. Interleukins: Pathogenesis in Non-Alcoholic Fatty Liver Disease. Metabolites 2024; 14 [PMID: 38535313 DOI: 10.3390/metabo14030153]
43 Ćurčić IB, Kizivat T, Petrović A, Smolić R, Tabll A, Wu GY, Smolić M. Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update. J Clin Transl Hepatol 2022; 10: 1186-1193 [PMID: 36381097 DOI: 10.14218/JCTH.2021.00501]
44 Udomsinprasert W. Interleukin-1 family cytokines in liver cell death: a new therapeutic target for liver diseases. Expert Opin Ther Targets 2023; 27: 1125-1143 [PMID: 37975716 DOI: 10.1080/14728222.2023.2285763]
45 Paliwal VM, Kundu S, Kulhari U, Jala A, Ishteyaque S, Borkar RM, Mugale MN, Murty US, Sahu BD. Alternanthera brasiliana L. extract alleviates carbon tetrachloride-induced liver injury and fibrotic changes in mice: Role of matrix metalloproteinases and TGF-β/Smad axis. J Ethnopharmacol 2023; 303: 115992 [PMID: 36509261 DOI: 10.1016/j.jep.2022.115992]